Korean J Hematol.  2012 Mar;47(1):8-16. 10.5045/kjh.2012.47.1.8.

Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation

  • 1Department of Internal Medicine, University of Washington School of Medicine, Seattle, WA, USA.
  • 2Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. agopal@u.washington.edu


Hodgkin lymphoma (HL) represents one of the great success stories in hematology going from a uniformly fatal disease, to one that is curable in the vast majority of cases. Despite this success, some patients experience relapse. To address this unmet need a variety of agents, classes of drugs, and strategies have demonstrated activity in HL recurring after autologous hematopoietic stem cell transplantation. These include chemotherapeutics (gemcitabine-based combinations, bendamustine), histone deacetylase (HDAC) inhibitors (panobinostat), immunomodulatory agents (lenalidomide), mTOR inhiobitors (everolimus), monoclonal antibodies (rituximab), and antibody-drug conjugates (brentuximab vedotin) as well the potential of long-term disease control via allogeneic transplantation. Such advances reflect our increased understanding of the biology of HL and hold promise for continued improved outcomes for those suffering with this condition.


Hodgkin lymphoma; Antibody drug conjugates; allogeneic transplant; HDAC inhibitor; IMID; mTOR
Full Text Links
  • KJH
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr